Compare VAL & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAL | TLX |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | Bermuda | Australia |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | VAL | TLX |
|---|---|---|
| Price | $50.89 | $7.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $54.80 | $21.00 |
| AVG Volume (30 Days) | ★ 1.0M | 204.3K |
| Earning Date | 02-18-2026 | 01-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.61 | 0.04 |
| Revenue | ★ $2,416,000,000.00 | $664,225,558.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $9.46 | $174.95 |
| Revenue Growth | 6.81 | ★ 55.35 |
| 52 Week Low | $27.15 | $7.38 |
| 52 Week High | $61.70 | $30.36 |
| Indicator | VAL | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 31.19 |
| Support Level | $49.70 | $7.38 |
| Resistance Level | $54.49 | $8.22 |
| Average True Range (ATR) | 1.84 | 0.17 |
| MACD | 0.25 | -0.02 |
| Stochastic Oscillator | 50.72 | 16.65 |
Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.